Immunocore
IMCR
45 hedge funds and large institutions have $561M invested in Immunocore in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 9 closing their positions.
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
10% more funds holding
Funds holding: 41 → 45 (+4)
0.66% more ownership
Funds ownership: 34.04% → 34.69% (+0.66%)
6% less capital invested
Capital invested by funds: $598M → $561M (-$36.7M)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$7.3M |
| 2 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
+$6.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.96M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$3.47M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.31M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$6.41M |
| 3 |
Millennium Management
New York
|
-$3.88M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.53M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.49M |
IMCR Hedge Fund Activity: Q2 2021 in Review
45 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q2 2021, worth a combined $561M — down 6.1% from $598M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IMCR positions and 9 closed out — a net gain of 4 holders — while 10 added to existing stakes and 12 trimmed.
The largest buyer was Deerfield Management, adding an estimated $7.3M. The largest seller was Fidelity Investments, cutting an estimated $7.31M.
- 45 institutional investors held Immunocore (IMCR) as of Q2 2021, up from 41 in Q1 2021.
- Funds reported $561M of Immunocore stock for Q2 2021, down 6.1% quarter-over-quarter.
- 13 funds opened new Immunocore positions in Q2 2021 and 9 closed out, a net change of +4 holders.
- The largest Immunocore buyer in Q2 2021 was Deerfield Management, an estimated $7.3M added.
- The largest Immunocore seller in Q2 2021 was Fidelity Investments, an estimated $7.31M sold.
Based on aggregated 13F filings for Q2 2021.